Reducing Cardiovascular Risk: Making Sense of the Latest Data and Guidelines

Reducing Cardiovascular Risk: Making Sense of the Latest Data and Guidelines is organized by National Association for Continuing Education (NACE).

Start Date: Oct 15, 2019
Expiration Date: Oct 14, 2020

Target Audience: Cardiologists and Primary Care Providers

Credit(s):
• 1.0 AMA PRA Category 1 Credit(s)™
• 1.0 AANP Contact Hour which includes 0.75 pharmacology hours

Summary:
Low density cholesterol (LDL-C) is causally associated with risk for cardiovascular disease, which is a common cause of morbidity and mortality. Lipid-lowering therapy can not only lower serum cholesterol but can also decrease adverse cardiovascular events and mortality. Statins have been the mainstay of hypercholesteremia management for many years, but despite the use of these agents, cardiovascular event rates remain relatively high, underpinning the need for novel therapies. High risk patients, such as those with familial hypercholesterolemia (FH), a disorder associated with a mutation in the gene coding for proprotein convertase subtilisin/kexin type 9 (PCSK9), can particularly benefit from newer therapies.

This activity will review the latest ACC/AHA mulit-society guidelines, examine how to incorporate the current data surrounding non-statin therapy into secondary prevention treatment strategies for patients with the highest cardiovascular risk, and how to overcome barriers to access for PCSK9 monoclonal antibody therapy.

This webcast was recorded live at the Conversations in Cardiology 2019 and is being used with the permission of the presenters.

Learning Objectives:
After completing this program participants should be able to:
• Discuss the latest 2018 ACC/AHA Multi-society Guideline on the Management of Blood Cholesterol to reduce the risk of cardiovascular disease
• Incorporate current data surrounding non-statin therapy into secondary prevention treatment strategies for patients with the highest cardiovascular risk
• Overcome barriers to access for PCSK9 monoclonal antibody therapy.

Additional details will be posted as soon as information is available.